CR20120202A - Métodos y composiciones para tratar cáncer - Google Patents

Métodos y composiciones para tratar cáncer

Info

Publication number
CR20120202A
CR20120202A CR20120202A CR20120202A CR20120202A CR 20120202 A CR20120202 A CR 20120202A CR 20120202 A CR20120202 A CR 20120202A CR 20120202 A CR20120202 A CR 20120202A CR 20120202 A CR20120202 A CR 20120202A
Authority
CR
Costa Rica
Prior art keywords
methods
compositions
treat cancer
equipment
pharmaceutical compositions
Prior art date
Application number
CR20120202A
Other languages
English (en)
Spanish (es)
Inventor
Wei-Sheng Huang
Victor M Rivera
Timothy P Clackson
William C Shakespeare
Rachel M Squillace
Joseph M Gozgit
Original Assignee
Ariad Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43922622&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20120202(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ariad Pharma Inc filed Critical Ariad Pharma Inc
Publication of CR20120202A publication Critical patent/CR20120202A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CR20120202A 2009-10-30 2012-04-25 Métodos y composiciones para tratar cáncer CR20120202A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25666909P 2009-10-30 2009-10-30
US25669009P 2009-10-30 2009-10-30
US26101409P 2009-11-13 2009-11-13

Publications (1)

Publication Number Publication Date
CR20120202A true CR20120202A (es) 2012-06-12

Family

ID=43922622

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20120202A CR20120202A (es) 2009-10-30 2012-04-25 Métodos y composiciones para tratar cáncer

Country Status (16)

Country Link
US (2) US20120316137A1 (https=)
EP (2) EP2762142A1 (https=)
JP (1) JP2013509444A (https=)
KR (1) KR20120115237A (https=)
CN (1) CN102770129A (https=)
AU (1) AU2010313152A1 (https=)
CA (1) CA2777128A1 (https=)
CL (1) CL2012001133A1 (https=)
CR (1) CR20120202A (https=)
EA (1) EA201290255A1 (https=)
IL (1) IL218987A0 (https=)
MX (1) MX2012005023A (https=)
NI (1) NI201200072A (https=)
PH (1) PH12012500809A1 (https=)
WO (1) WO2011053938A1 (https=)
ZA (1) ZA201202256B (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2495016T1 (sl) 2005-12-23 2020-04-30 Ariad Pharmaceuticals, Inc. Biciklične heteroarilne spojine
CA2856803A1 (en) * 2011-11-23 2013-05-30 Intellikine, Llc Enhanced treatment regimens using mtor inhibitors
CN103570724B (zh) * 2012-07-27 2015-12-16 中国科学院广州生物医药与健康研究院 ponatinib 的合成方法
US10172796B2 (en) 2012-12-03 2019-01-08 Manli International Ltd. Use of umirolimus and its derivatives for treating cancer
CA3022250A1 (en) * 2012-12-12 2014-06-12 Ariad Pharmaceuticals, Inc. Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride
AU2013204506B2 (en) * 2012-12-13 2016-05-05 Takeda Pharmaceuticals U.S.A., Inc. Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride
KR20150123250A (ko) 2013-03-06 2015-11-03 제넨테크, 인크. 암 약물 내성의 치료 및 예방 방법
US20140343282A1 (en) 2013-05-16 2014-11-20 Apicore, Llc Processes for making ponatinib and intermediates thereof
US9725454B2 (en) 2013-07-04 2017-08-08 Sandoz Ag Crystalline forms of ponatinib hydrochloride
KR20160045072A (ko) * 2013-07-30 2016-04-26 프레제니우스 카비 도이치란트 게엠베하 혈액학적 신생물의 치료를 위한 하이드록시알킬 전분
CN104650086A (zh) * 2013-11-22 2015-05-27 天津市汉康医药生物技术有限公司 盐酸帕纳替尼化合物
WO2015085973A1 (en) * 2013-12-09 2015-06-18 Zentiva, K.S. Modifications of 3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl] benzamide hydrochloride salt
WO2015085972A1 (en) * 2013-12-09 2015-06-18 Zentiva, K.S. NOVEL SALTS OF 3-(2-IMIDAZO[1,2-b]PYRIDAZIN-3-YLETHYNYL)-4-METHYL-N-[4-[(4-METHYL- 1-PIPERAZINYL)METHYL]-3-(TRIFLUOROMETHYL)PHENYL] BENZAMIDE
WO2015085971A1 (en) * 2013-12-09 2015-06-18 Zentiva, K.S. Hydrobromide salt of 3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl] benzamide
PL3087051T3 (pl) * 2013-12-24 2021-02-22 Oncotartis Inc. Związki benzamidowe i nikotynamidowe oraz sposoby ich stosowania
CN104496995A (zh) * 2014-01-06 2015-04-08 广东东阳光药业有限公司 制备3-乙炔基咪唑并[1,2-b]哒嗪的方法
CN107073121A (zh) 2014-06-13 2017-08-18 基因泰克公司 治疗及预防癌症药物抗性的方法
CN105267200A (zh) * 2014-07-01 2016-01-27 中国科学院上海有机化学研究所 一种黄酮类化合物的应用
US10202365B2 (en) 2015-02-06 2019-02-12 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
PL3371171T3 (pl) 2015-11-02 2024-03-25 Blueprint Medicines Corporation Inhibitory RET
TW201738228A (zh) 2016-03-17 2017-11-01 藍圖醫藥公司 Ｒｅｔ之抑制劑
EP3443001B1 (en) 2016-04-11 2025-04-30 Obsidian Therapeutics, Inc. REGULATED BIOCIRCUIT SYSTEMS
US10227329B2 (en) 2016-07-22 2019-03-12 Blueprint Medicines Corporation Compounds useful for treating disorders related to RET
CN106236732A (zh) * 2016-08-31 2016-12-21 佛山市弘泰药物研发有限公司 一种依维莫司软胶囊的制备方法
EA201991197A1 (ru) * 2016-12-15 2020-01-13 Ариад Фармасьютикалз, Инк. БЕНЗИМИДАЗОЛЬНЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ c-Kit
CN108047230B (zh) * 2017-12-29 2020-04-17 深圳蓝新科技有限公司 帕纳替尼的制备方法
SI3773589T1 (sl) 2018-04-03 2024-03-29 Blueprint Medicines Corporation Inhibitor RET za uporabo pri zdravljenju raka, ki ima RET spremembo
CN109875999B (zh) * 2018-05-29 2022-07-12 上海交通大学医学院附属第九人民医院 泊那替尼在kit突变型恶性黑色素瘤中的应用
EP3781568A1 (en) 2018-06-22 2021-02-24 Johnson Matthey Public Limited Company Form of ponatinib
US20220003750A1 (en) * 2018-12-01 2022-01-06 The Regents Of The University Of Colorado, A Body Corporate Functional screen for small molecule and monoclonal antibody drug sensitivity in multiple myeloma patients
US12097195B2 (en) 2019-12-09 2024-09-24 Ascentage Pharma (Suzhou) Co., Ltd. Pharmaceutical composition containing alkynyl compound and preparation method and application thereof
WO2021225980A1 (en) * 2020-05-04 2021-11-11 Dna-Seq, Inc. Methods and systems for determination of an effective therapeutic regimen and drug discovery
JP2023527412A (ja) 2020-05-29 2023-06-28 ブループリント メディシンズ コーポレイション プラルセチニブの固体形態
WO2022105836A1 (en) * 2020-11-19 2022-05-27 Guangzhou Healthquest Pharma Co., Ltd. Combination therapies for treating cancer
CN114796227B (zh) * 2022-05-30 2023-12-01 中山大学 Ponatinib在制备预防或治疗血管退行性疾病药物中的应用及该药物

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US4316885A (en) 1980-08-25 1982-02-23 Ayerst, Mckenna And Harrison, Inc. Acyl derivatives of rapamycin
US4650803A (en) 1985-12-06 1987-03-17 University Of Kansas Prodrugs of rapamycin
US5023264A (en) 1990-07-16 1991-06-11 American Home Products Corporation Rapamycin oximes
US5023263A (en) 1990-08-09 1991-06-11 American Home Products Corporation 42-oxorapamycin
US5221670A (en) 1990-09-19 1993-06-22 American Home Products Corporation Rapamycin esters
US5233036A (en) 1990-10-16 1993-08-03 American Home Products Corporation Rapamycin alkoxyesters
US5120842A (en) 1991-04-01 1992-06-09 American Home Products Corporation Silyl ethers of rapamycin
US5100883A (en) 1991-04-08 1992-03-31 American Home Products Corporation Fluorinated esters of rapamycin
US5118678A (en) 1991-04-17 1992-06-02 American Home Products Corporation Carbamates of rapamycin
US5118677A (en) 1991-05-20 1992-06-02 American Home Products Corporation Amide esters of rapamycin
US5162333A (en) 1991-09-11 1992-11-10 American Home Products Corporation Aminodiesters of rapamycin
US5177203A (en) 1992-03-05 1993-01-05 American Home Products Corporation Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5480988A (en) 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US5411967A (en) 1992-10-13 1995-05-02 American Home Products Corporation Carbamates of rapamycin
US5302584A (en) 1992-10-13 1994-04-12 American Home Products Corporation Carbamates of rapamycin
US5480989A (en) 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US5434260A (en) 1992-10-13 1995-07-18 American Home Products Corporation Carbamates of rapamycin
US5489680A (en) 1992-10-13 1996-02-06 American Home Products Corporation Carbamates of rapamycin
US5262423A (en) 1992-10-29 1993-11-16 American Home Products Corporation Rapamycin arylcarbonyl and alkoxycarbonyl carbamates as immunosuppressive and antifungal agents
US5258389A (en) 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
US5260300A (en) 1992-11-19 1993-11-09 American Home Products Corporation Rapamycin carbonate esters as immuno-suppressant agents
US5504091A (en) 1993-04-23 1996-04-02 American Home Products Corporation Biotin esters of rapamycin
US5378836A (en) 1993-10-08 1995-01-03 American Home Products Corporation Rapamycin oximes and hydrazones
US5373014A (en) 1993-10-08 1994-12-13 American Home Products Corporation Rapamycin oximes
US5391730A (en) 1993-10-08 1995-02-21 American Home Products Corporation Phosphorylcarbamates of rapamycin and oxime derivatives thereof
US5385908A (en) 1993-11-22 1995-01-31 American Home Products Corporation Hindered esters of rapamycin
US5385910A (en) 1993-11-22 1995-01-31 American Home Products Corporation Gem-distributed esters of rapamycin
US5385909A (en) 1993-11-22 1995-01-31 American Home Products Corporation Heterocyclic esters of rapamycin
US5389639A (en) 1993-12-29 1995-02-14 American Home Products Company Amino alkanoic esters of rapamycin
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5463048A (en) 1994-06-14 1995-10-31 American Home Products Corporation Rapamycin amidino carbamates
US5491231A (en) 1994-11-28 1996-02-13 American Home Products Corporation Hindered N-oxide esters of rapamycin
US5563145A (en) 1994-12-07 1996-10-08 American Home Products Corporation Rapamycin 42-oximes and hydroxylamines
US5780462A (en) 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
US6258823B1 (en) 1996-07-12 2001-07-10 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
TW557297B (en) 1997-09-26 2003-10-11 Abbott Lab Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same
JP2000119181A (ja) 1998-10-06 2000-04-25 Kureha Chem Ind Co Ltd エスクレチン及びその誘導体の放出制御経口製剤
AU783158B2 (en) 1999-08-24 2005-09-29 Ariad Pharmaceuticals, Inc. 28-epirapalogs
US6277983B1 (en) 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives
JP4547911B2 (ja) 2002-02-01 2010-09-22 アリアド・ファーマシューティカルズ・インコーポレイテッド リン含有化合物およびその用途
GB0229022D0 (en) * 2002-12-12 2003-01-15 Novartis Ag Organic Compounds
EP1648900A4 (en) 2003-07-11 2010-02-10 Ariad Pharma Inc PHOSPHORUS MACROCYCLES
WO2005063720A1 (ja) * 2003-12-25 2005-07-14 Nippon Shinyaku Co., Ltd. アミド誘導体及び医薬
GB0512324D0 (en) * 2005-06-16 2005-07-27 Novartis Ag Organic compounds
GB0417905D0 (en) * 2004-08-11 2004-09-15 Novartis Ag Organic compounds
AU2006217744A1 (en) 2005-02-25 2006-08-31 Kudos Pharmaceuticals Limited 2,4-diamino-pyridopyrimidine derivatives and their use as MTOR inhibitors
GB0504994D0 (en) 2005-03-11 2005-04-20 Biotica Tech Ltd Novel compounds
CN101389338B (zh) * 2005-12-23 2013-06-26 阿里亚德医药股份有限公司 双环杂芳基化合物
SI2495016T1 (sl) * 2005-12-23 2020-04-30 Ariad Pharmaceuticals, Inc. Biciklične heteroarilne spojine
JP2009523161A (ja) 2006-01-11 2009-06-18 アストラゼネカ アクチボラグ モルホリノピリミジン誘導体と療法におけるその使用
ES2400375T3 (es) * 2006-04-07 2013-04-09 Novartis Ag Combinación que comprende A) un compuesto de pirimidilaminobenzamida y B)un inhibidor de cinasa THR315LLE
EP2016075A1 (en) 2006-05-03 2009-01-21 AstraZeneca AB Thiazole derivatives and their use as anti-tumour agents
WO2007135398A1 (en) 2006-05-22 2007-11-29 Astrazeneca Ab Indole derivatives
MX2009002046A (es) 2006-08-24 2009-03-06 Astrazeneca Ab Derivados de morfolino pirimidina utiles en el tratamiento de trastornos proliferativos.
JP2010501537A (ja) 2006-08-24 2010-01-21 アストラゼネカ アクチボラグ 増殖性障害の治療に有用なモルホリノピリミジン誘導体
WO2008032033A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab 4-benzimidazolyl-2-morpholino-6-piperazinylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
WO2008032036A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab 6-benzimidaz0lyl-2-m0rph0lin0-4- (azetidine, pyrrolidine, piperidine or azepine) pyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
WO2008032089A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab 4-benzimidaz0lyl-2-m0rph0lin0-6-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
WO2008032060A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab 4-benzimidaz0lyl-6-m0rph0lin0-2-piperazinylpyrimidine derivatives as p13k and mtor inhibitors for the treatment of proliferative disorders
WO2008032091A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab 4-benzimidaz0lyl-6-m0rph0lin0-2-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
WO2008032041A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab Pyrimidine derivatives having inhibitory activity against pi3k enzymes
WO2008032077A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab Pyrimidine derivatives
CN101595103A (zh) 2006-09-14 2009-12-02 阿斯利康(瑞典)有限公司 嘧啶衍生物
US20090105270A1 (en) * 2007-02-20 2009-04-23 Buser-Doepner Carolyn A Kinase inhibition and anticancer therapy
EP2178563A2 (en) 2007-07-06 2010-04-28 OSI Pharmaceuticals, Inc. Combination anti-cancer therapy comprising an inhibitor of both mtorc1 and mtorc2
CA2692945A1 (en) 2007-07-09 2009-01-15 Astrazeneca Ab Compounds - 945
EP2178866A2 (en) 2007-07-09 2010-04-28 AstraZeneca AB Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
CN101809002B (zh) 2007-07-09 2013-03-27 阿斯利康(瑞典)有限公司 用于与mtor激酶和/或pi3k相关的疾病中的吗啉代嘧啶衍生物
WO2009007751A2 (en) 2007-07-09 2009-01-15 Astrazeneca Ab Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
EP2222166B9 (en) * 2007-12-10 2012-11-07 Concert Pharmaceuticals Inc. Heterocyclic kinase inhibitors
EP2611443A2 (en) * 2010-09-01 2013-07-10 ArQule, Inc. Methods for treatment of non-small cell lung cancer

Also Published As

Publication number Publication date
EP2762142A1 (en) 2014-08-06
IL218987A0 (en) 2012-06-28
ZA201202256B (en) 2012-12-27
KR20120115237A (ko) 2012-10-17
EP2493460A4 (en) 2013-04-24
PH12012500809A1 (en) 2012-11-26
CL2012001133A1 (es) 2013-08-02
WO2011053938A1 (en) 2011-05-05
US20120316137A1 (en) 2012-12-13
MX2012005023A (es) 2012-06-19
AU2010313152A1 (en) 2012-04-19
US20130178622A1 (en) 2013-07-11
EP2493460A1 (en) 2012-09-05
CN102770129A (zh) 2012-11-07
EA201290255A1 (ru) 2013-04-30
CA2777128A1 (en) 2011-05-05
WO2011053938A8 (en) 2011-08-11
NI201200072A (es) 2012-08-20
JP2013509444A (ja) 2013-03-14

Similar Documents

Publication Publication Date Title
CR20120202A (es) Métodos y composiciones para tratar cáncer
MX2015011897A (es) Profarmacos de fumaratos y su uso en el tratamiento de diferentes enfermedades.
MX2014010455A (es) Metodos y composiciones para tratar enfermedad de huntington.
EA201171367A1 (ru) Винилиндазолильные соединения
MX2016002544A (es) Compuestos utiles como inmunomoduladores.
MX2014011134A (es) Compuestos de carbamato y preparacion y uso de los mismos.
TR201813877T4 (tr) Spi̇nal müsküler atrofi̇ni̇n tedavi̇ edi̇lmesi̇ne yöneli̇k bi̇leşi̇kler.
MY184101A (en) Indoles
CL2014002873A1 (es) Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer.
BR112013002012A2 (pt) métodos e composições para terapia de câncer de fígado
BR112015001838A2 (pt) composições de inibidor de efluxo e métodos de tratamento utilizando o mesmo.
MX360404B (es) Compuestos para inhibir la proliferacion celular en canceres transmitidos por egfr.
BR112012030699A2 (pt) métodos para tratar câncer de bexiga
MX343135B (es) Compuestos de tipo fumagilol y métodos de realización y uso de los mismos.
BR112015011756A2 (pt) inibidores da glutamase e métodos de uso
WO2014052836A3 (en) Methods and compositions for treating infection
NZ628294A (en) Compositions and methods of use of phorbol esters for the treatment of stroke
HN2012000023A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
NZ708727A (en) Conjugate compounds
BRPI1007972A2 (pt) composições de combinação e métodos para o tratamento de câncer
MX356755B (es) Compuestos de tipo fumagilol y metodos para su elaboración y uso.
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
BR112014030416A2 (pt) composto, métodos para a inibição da tankyrase 1 e para o tratamento do câncer, utilização de um composto, composição e invenção.
BRPI1007995A2 (pt) orto-aminoamidas para o tratamento de cãncer.
AU2013225816A8 (en) Compositions and methods for treating Type III Gaucher Disease